Use of Decametoxinum in bronchiectasis

Gashynova, Kateryna and Suska, Kseniia and Dmytrychenko, Valeriia (2020) Use of Decametoxinum in bronchiectasis. European Respiratory Journal, 56 (S. 64). p. 2371. ISSN 0903-1936 (Print); 1399-3003 (Online)

Text Use of Decametoxinum in bronchiectasis _ European Respiratory Society.pdf Download (291kB)

Abstract

The respiratory microbiota in patients (p) with bronchiectasis (B) plays a great role in the etiology and pathogenesis of B. The study aimed to determine lung microbiota composition during stable disease and the effect of Decametoxinum (DECASAN®) inhalations on it. Cohort of pin stable phase with confirmed by HRCT B was included. Isolation and identification of pathogens were conducted by bacteriological methods. Nebulized inhalations of antimicrobial drug DECASAN® (0.8 mg) were carried out twice a day, duration-14 days. Sputum samples were examined on the baseline and after 14 days of treatment. 60 p were examined. The average age -52.9±14.3 years, 15 of them were men (25%). Pathogens were detected in 37 (61.7%) samples (s), the combination of pathogens in seven (11.7%) patients. P.aeruginosa (PA) was identificated in 13 (21.7%) s, it`s combination with H.influenza in one patient (1.7%) and A.niger in one patient (1.7%). Among the pathogens identified in the remaining 24 patients were: H.influenza – in 13 s (21.7%), H.parainfluenza – in one patient (1.7%), NF gram negative bacilli – in one patient (1.7%), S.aureus – in two patients (3.4%), C.albicans – in four patients (6.8%), S.pneumoniae in two patients (3.4%), A.niger in one patient (1.7%). DECASAN® took 24 p, five p had combination of pathogens (p without sputum colonization and p colonized by PA were excluded). Their median bacterial load at the beginning of treatment was 6 log10 CFU*g-1 (5; 7.5), after 14 days - 4 log10CFU*g-1 (0; 6). P on the treatment had a significant reduction (p=0.0006 by the Wilcoxon test) in total sputum bacterial load. 10 (41.7 %) out of 24 subjects reported pathogen eradication. DECASAN® showed effectiveness in p with colonized sputum by non-PA pathogens.

Item Type:	Article
Additional Information:	European Respiratory Journal 2020; 56: Suppl. 64, 2371. DOI: 10.1183/13993003.congress-2020.2371 This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.
Uncontrolled Keywords:	bronchiectasis, microbiota
Subjects:	Internal Medicine
Divisions:	Departments > Department of occupational diseases, clinical immunology and clinical pharmacology
Depositing User:	Елена Шрамко
Date Deposited:	15 Nov 2021 08:51
Last Modified:	18 Nov 2021 09:18
URI:	http://repo.dma.dp.ua/id/eprint/7106

Actions (login required)

View Item